The Board has instituted IPR2016-00408 and IPR2016-00409 on AbbVie Biotechnology’s U.S. Patent No. 8,889,135, which covers methods of treating rheumatoid arthritis with a human anti-tumor necrosis factor α antibody. This patent relates to AbbVie’s Humira®.
IPR2016-00172 filed by Coherus BioSciences Inc. was also instituted against this patent earlier this year.